Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.
Researchers sought to determine whether C-CAR039 would be safe and effective in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Researchers sought to determine whether pirtobrutinib would be effective and tolerable in heavily pretreated patients with mantle cell lymphoma.
Researchers sought to update and assess the interim efficacy, futility, and safety in the phase 3 SPARKLE trial.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
The ZUMA-5 trial studied whether CAR T cell therapy with axi-cel had any clinical benefits in patients with indolent NHL.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
The bispecific CAR-T therapy targets CD20 and CD19.
